Welcome back to the CPHI Exhibitor Spotlight!
.png)
We’re continuing our journey through the standout companies heading to CPHI Americas 2025, and next up is Adare - a global leader known for turning complex formulation challenges into innovative, patient-centric solutions.
From advanced drug delivery technologies to specialized CDMO services, Adare brings deep expertise and a proven track record to the spotlight. Ready to see how they’re making an impact in pharma?
Let’s dive in.
What exciting innovations or products will you be showcasing at CPHI Americas?
3D Screen Printing
In collaboration with Laxxon Medical, Adare Pharma Solutions is now providing 3D screen printing capabilities to our customers. This technology represents a transformative opportunity for drug development by enabling complex drug delivery systems that simply can't be achieved via traditional methods.
3D screen printing is a scalable, additive manufacturing process that facilitates precise, layer-by-layer construction of drug formulations. This allows integration of immediate, extended, delayed, and sequential release mechanisms within a single tablet. We can also use the technology to easily incorporate multiple APIs with distinct pharmacokinetic profiles into one dosage form, offering unprecedented therapeutic flexibility.
As personalized medicine and patient-centric therapies become the norm, we’re going to see 3D screen printing play a major role in helping sponsors bring smarter, more targeted products to market.
MMTS™ Minitabs
We'll also be showcasing our MMTS™ Minitabs technology, which combines the simplicity and high drug-loading capacity of tablets with the flexibility to deliver a wide range of release profiles tailored to both patient needs and drug characteristics.
This multiparticulate dosage form enables the delivery of dozens or even hundreds of cylindrical Minitabs (1.0–2.0 mm) in convenient formats such as capsules, sachets, or sprinkles. Each Minitab contains the active pharmaceutical ingredient (API) and excipients enclosed within specialized polymer coatings that precisely control drug dissolution and diffusion.
Supported by Adare’s robust commercial-scale manufacturing capabilities and validated clinical performance, MMTS Minitabs can help overcome key formulation challenges, including dose precision, patient compliance, and therapeutic efficacy.
Why did you choose to exhibit at this event?
We're delighted to exhibit at CPHI Americas because it’s a premier pharmaceutical industry event that's hosted in our own backyard: Philadelphia, a vital and growing hub for life sciences. As a global CDMO headquartered in Philly, we’re proud to support and engage with the industry here.
CPHI Americas, like its sister show CPHI Worldwide, brings together pharma professionals, innovators, and businesses of all sizes to connect, collaborate, and explore the future of pharmaceutical development.
Unlike smaller and more specialized events, CPHI Americas offers access to representatives from the entire pharmaceutical supply chain under one roof. That’s especially valuable for a company like Adare, which provides end-to-end services from development to commercial manufacturing that allow us to seamlessly scale and commercialize complex products across our global and regional manufacturing capabilities.
Who would you like to meet at the event?
We’d love to meet pharmaceutical companies looking for a trusted CDMO partner to support them from early development through commercial manufacturing and packaging.
We’re especially eager to connect with teams developing small molecule oral dosage forms who are seeking expertise in customized release profiles, taste masking, or patient-centric dosing.
We’re also interested in speaking with companies in need of a globally integrated partner with the capacity and experience to bring complex formulations to market efficiently. With seven facilities across the US and Europe and over 65 products developed and manufactured for our customers, Adare has extensive experience executing smooth, efficient tech transfers, both for products in development and for commercialized therapies needing a new manufacturing partner. Whether customers are launching a new product or optimizing supply of an established product, we can provide the technical depth, regulatory expertise, and operational flexibility to meet evolving needs and ensure long-term success.
Finally, we’d like to meet with companies who are looking for a development and manufacturing partner with a strong global and regional presence. With facilities in the world’s two largest pharmaceutical markets, the U.S. and Europe, Adare offers regional access, supply chain flexibility, and the operational resilience needed to keep projects moving forward.

Related News
-
News Tracking Innovation with Thermo Fisher Scientific: CPHI Americas Track Sponsor interview
As we gear up for CPHI Americas from May 20-22, 2025 at the Philadelphia Convention Center, we sat down with Track Sponsor Thermo Fisher Scientific to discuss the future of bioproduction in pharma.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News Executive order to elevate US pharma manufacturing signed by Trump
On Monday, May 5, US President Trump signed an executive order to reduce regulatory barriers for domestic US pharmaceutical manufacturing, including key ingredients and materials for manufacturing prescription drugs.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News China import tax fine could cost AstraZeneca up to US$8 million
British-Swedish drugmaker AstraZeneca could find itself facing fines of up to US$8million in China due to suspected unpaid import taxes on breast cancer drug Enhertu.
-
News Women in Pharma: Building from the ground up together
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pharmaceutical Packaging Market Prospects – Innovations in Packaging and Drug Delivery
Download the Pharmaceutical Packaging Market Prospects Trend Report to explore the full report and delve into the evolving opportunities in pharmaceutical packaging and drug delivery.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance